In the Spotlight...
First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Metastatic Melanoma Patients
Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform
iPSC-derived trimodal T cells engineered with CAR, TCR, and hnCD16 modalities can overcome antigen escape in heterogeneous tumors
UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity
Previous Digests
Dimming IFN signaling to brighten CAR-T persistence and efficacy
June 18, 2025
While CAR T cell therapy has shown great success in hematological cancers, relapses may occur, and the therapy has so far shown limited efficacy in solid tumors. Based on their previous data, which showed that genetic deletion of IFNγ...
A new off-the-shelf CAR T cell product made from iPSCs
June 11, 2025
CAR T cell therapies are well known for their potent capacity for killing antigen-expressing target cells. However, they are often hindered by factors in solid tumors and by challenges related to the development of an autologous T cell product...
Non-mutated tumor antigens in the spotlight for therapeutic targeting
June 4, 2025
Recent discoveries of unmutated aberrantly expressed tumor-specific antigens (aeTSAs) derived from non-coding regions and embryonic transcriptional programs has garnered attention as targets for immunotherapy. Apavaloaei et al. explored cell surface presentation of peptide:MHCs derived from mutated and unmutated tumor...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ed Fritsch
Ute Burkhardt
Lauren Hitchings
Gaelle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.
Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).
Current Sponsors
